IRIDEX Corporation (IRIX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IRIX currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.72) and Max Pain ($0.76) forces dealer call-delta covering toward $1.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
IRIDEX Corporation (IRIX) dropped -2.92% to $0.72, trading at 11% of its 52-week range ($0.61 – $1.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRIX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, IRIDEX Corporation (IRIX) ranks #854 by composite RQD confidence (34/100, grade E) and #872 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, IRIX leads on earnings valuation at N/A trailing P/E, while IRIX leads on capital efficiency and profitability with -35.0% ROIC and 36.5% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with IRIX at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRIX
ACTIVE
IRIDEX Corporation | E | 34/100 | — | 36.5% | -35.0% | -2.92% | $12.7M | Benchmark Subject |
| ITOC iTonic Holdings Ltd (Class A) | D- | 35/100 | — | 62.6% | -35.0% | -4.99% | $20.9M | /itoc-vs-irix → |
| NDRA ENDRA Life Sciences Inc. | D | 48/100 | — | — | -35.0% | +2.95% | $7.3M | /ndra-vs-irix → |
| QTI QT Imaging Holdings Inc. | D- | 38/100 | — | 45.4% | -35.0% | -3.07% | $32.3M | /qti-vs-irix → |
| POCI Precision Optics Corporation Inc. | E | 34/100 | — | 17.8% | -35.0% | +5.76% | $50.5M | /poci-vs-irix → |
In its most recent audited fiscal period (FY2025, filed 2026-01-03), IRIDEX Corporation (IRIX) reported GAAP revenue of $52.7M (+8.2% vs. FY2024 revenue of $48.7M , and +1.6% cumulative change since FY2023) , GAAP net income of -$4.4M, operating cash flow of -$2.1M, and free cash flow of -$2.3M (+69.1% YoY). On the balance sheet, IRIX closed FY2025 with $29.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-01-03 | $52.7M | -$4.4M | -$2.1M | -$2.3M | $29.2M | — |
| FY2024 (FY) | 2024-12-28 | $48.7M | -$8.9M | -$7.3M | -$7.3M | $29.1M | — |
| FY2023 (FY) | 2023-12-30 | $51.9M | -$9.6M | -$6.7M | -$6.7M | — | — |
As of 2026-11-01, IRIDEX Corporation (NASDAQ: IRIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.72 (-2.92% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRIX ranks #854 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), IRIX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 36.5%, and ROIC of -35.0%. By comparison, ITOC (iTonic Holdings Ltd (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M) and NDRA (ENDRA Life Sciences Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $7.3M). Among the 5-stock peer group, IRIX leads on earnings multiple (N/A) while IRIX leads on capital efficiency (-35.0% ROIC).
Per IRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-01-03, CIK 0001006045), IRIDEX Corporation generated $52.7M in revenue (+8.2% YoY), -$4.4M in net income, and -$2.3M in free cash flow against $29.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IRIX last traded at $0.72 (-2.92% on volume of 26,381 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.72) and -30.77% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.61 to $1.65, IRIX sits at the 10.6% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).
Why IRIX Stock dropped -2.92% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.